

## **APPENDIX A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS**

The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99–499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological profiles for each substance included on the priority list of hazardous substances; and assure the initiation of a research program to fill identified data needs associated with the substances.

The toxicological profiles include an examination, summary, and interpretation of available toxicological information and epidemiologic evaluations of a hazardous substance. During the development of toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of cancer effects. These substance-specific estimates, which are intended to serve as screening levels, are used by ATSDR health assessors to identify contaminants and potential health effects that may be of concern at hazardous waste sites. It is important to note that MRLs are not intended to define clean-up or action levels.

MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor approach. They are below levels that might cause adverse health effects in the people most sensitive to such chemical-induced effects. MRLs are derived for acute (1–14 days), intermediate (15–364 days), and chronic (365 days and longer) durations and for the oral and inhalation routes of exposure. Currently, MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end point considered to be of relevance to humans. Serious health effects (such as irreparable damage to the liver or kidneys, or birth defects) are not used as a basis for establishing MRLs. Exposure to a level above the MRL does not mean that adverse health effects will occur.

## APPENDIX A

MRLs are intended only to serve as a screening tool to help public health professionals decide where to look more closely. They may also be viewed as a mechanism to identify those hazardous waste sites that are not expected to cause adverse health effects. Most MRLs contain a degree of uncertainty because of the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, elderly, nutritionally or immunologically compromised) to the effects of hazardous substances. ATSDR uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health principle of prevention. Although human data are preferred, MRLs often must be based on animal studies because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes that humans are more sensitive to the effects of hazardous substance than animals and that certain persons may be particularly sensitive. Thus, the resulting MRL may be as much as 100-fold below levels that have been shown to be nontoxic in laboratory animals.

Proposed MRLs undergo a rigorous review process: Health Effects/MRL Workgroup reviews within the Division of Toxicology, expert panel peer reviews, and agency-wide MRL Workgroup reviews, with participation from other federal agencies and comments from the public. They are subject to change as new information becomes available concomitant with updating the toxicological profiles. Thus, MRLs in the most recent toxicological profiles supersede previously published levels. For additional information regarding MRLs, please contact the Division of Toxicology, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, Mailstop F-32, Atlanta, Georgia 30333.

## APPENDIX A

**MINIMAL RISK LEVEL (MRL) WORKSHEET**

Chemical Name: Hydrogen Sulfide  
CAS Number: 7783-06-4  
Date: September 17, 2004  
Profile Status: Final Pre-Public Comment Draft  
Route: ☒ Inhalation ☐ Oral  
Duration: ☒ Acute ☐ Intermediate ☐ Chronic  
Graph Key: 16  
Species: Human

Minimal Risk Level: 0.2 ☐ mg/kg/day ☒ ppm

Reference: Jäppinen P, Vikka V, Marttila O, et al. 1990. Exposure to hydrogen sulphide and respiratory function. Br J Intern Med 47:824-828.

Experimental design: This study evaluated lung function in three male and seven female subjects with bronchial asthma requiring medication for 1–13 years; none of the subjects had severe asthma. The subjects were exposed to 2 ppm hydrogen sulfide for 30 minutes. Respiratory function in response to a histamine challenge was assessed prior to exposure and after exposure.

Effects noted in study and corresponding doses: No statistically significant changes in forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), and forced expiratory flow were noted. Airway resistance (Raw) and specific airway conductance (SGaw) did not show statistically significant changes when examined as a group. In two subjects, there were changes of over 30% in both Raw and SGaw; these changes were suggestive of bronchial obstruction. Additionally, 3 of 10 subjects complained of headaches after exposure.

Dose and end point used for MRL derivation:

☐ NOAEL ☒ LOAEL

At 2 ppm, no statistically significant alterations in lung function were observed. However, 2 of 10 individuals showed changes in airway resistance and specific airway conductance in excess of 30%.

Uncertainty Factors used in MRL derivation:

- ☒ 3 for use of a minimal LOAEL
- ☐ 10 for extrapolation from animals to humans
- ☒ 3 for human variability

Was a conversion used from ppm in food or water to a mg/body weight dose? None.

If an inhalation study in animals, list the conversion factors used in determining human equivalent dose: None.

Other additional studies or pertinent information which lend support to this MRL: Bhambhani et al. (1996b) evaluated the acute effects of hydrogen sulfide on the physiological and hematological health of male and female volunteers exposed to 5 ppm during two 30-minute sessions of submaximal exercise (50% of maximum aerobic power). No significant changes in any parameter were noted in the women,

## APPENDIX A

whereas the men showed a significant decrease in muscle citrate synthetase as well as nonsignificant changes in lactate, lactate dehydrogenase, and cytochrome oxidase. Together, these changes were considered indicative of compromise of aerobic metabolism.

No respiratory or cardiovascular effects were observed in 16 male volunteers exposed by oral inhalation to hydrogen sulfide at 0.5, 2, or 5 ppm for more than 16 minutes while exercising (Bhambhani and Singh 1991). The end points examined included heart rate, oxygen uptake, carbon dioxide output, and blood gases. Airway resistance and conductance were not measured in this study. No significant changes in pulmonary function parameters were noted in individuals exposed to 10 ppm hydrogen sulfide for 15 minutes during exercise (Bhambhani et al. 1996).

Respiratory distress was noted in two workers exposed to >40 ppm hydrogen sulfide for under 25 minutes (Spolyar 1951). In animals, impacts on the respiratory system such as increases in the cellularity and lactate dehydrogenase and alkaline phosphatase activities of bronchial lavage fluids have been seen at exposures as low as 10 ppm for 4 hours (Lopez et al. 1987), although without a dose-related trend.

A significant dose-related decrease in lung microsomal cytochrome c oxidase activity was seen in rats following a 4-hour exposure to 50, 200, or 400 ppm hydrogen sulfide (Khan et al. 1990). Similarly, succinate oxidase activity also decreased in a dose-related fashion; although no effect was observed at the lowest dose. Cytochrome oxidase levels returned to normal by 24 hours postexposure in animals in the 200 ppm group, but not the 400 ppm group. Exposure at the two higher dose levels was also associated with complete abolition of the zymosan-induced stimulation of respiratory rates of pulmonary alveolar macrophages and there were significant decreases in the number of viable macrophages in lung lavage fluids at the highest dose (Khan et al. 1991). Rats exposed to much higher levels (375 or 399 ppm for 4 hours) developed moderate to massive pulmonary edema (Prior et al. 1990).

Agency Contact (Chemical Manager): Selene Chou

## APPENDIX A

**MINIMAL RISK LEVEL (MRL) WORKSHEET**

Chemical Name: Hydrogen Sulfide  
CAS Number: 7783-06-4  
Date: September 17, 2004  
Profile Status: Final Pre-Public Comment Draft  
Route: ☒ Inhalation ☐ Oral  
Duration: ☐ Acute ☒ Intermediate ☐ Chronic  
Graph Key: 39  
Species: Sprague-Dawley rats

Minimal Risk Level: 0.02 ☐ mg/kg/day ☒ ppm

Reference: Brenneman KA, James RA, Gross EA, et al. 2000. Olfactory neuron loss in adult male CD rats following subchronic inhalation exposure to hydrogen sulfide. Toxicol Pathol 28:326-333.

Experimental design: Groups of male Sprague-Dawley rats (12/group) were exposed to 0, 10, 30, or 80 ppm hydrogen sulfide 6 hours/day, 7 days/week for 10 weeks. End points examined were limited to the nose; six transverse levels of the nose were examined via light microscopy.

Effects noted in study and corresponding concentrations: Nasal lesions were limited to the olfactory mucosa in rats exposed to 30 or 80 ppm and consisted of multifocal, bilaterally symmetrical olfactory neuron loss and basal cell hyperplasia affecting the lining of the dorsal medial meatus and the dorsal and medial regions of the ethmoid recess. In most cases, the incidence, mean severity, and distribution of exposure-related lesions increased in a concentration-related manner. The severity of the olfactory lesions were scored as 1 mild, 2 moderate, or 3 severe. For the olfactory neuron loss, the mild, moderate, or severe severity scores corresponded to 26–50, 51–75, and 76–100%, respectively, reduction in the normal thickness of the olfactory neuron layer; for the basal cell hyperplasia, mild, moderate, or severe severity scores corresponded to 1–33, 34–67, or 68–100% of the normal thickness of the olfactory neuron cell layer replaced by basal cells. The basal cell hyperplasia is a regenerative response to the loss of olfactory neurons. No olfactory lesions were observed in the controls or rats exposed to 10 ppm. At 30 ppm, the olfactory neuron loss was observed at nasal levels 4 (11/12, severity 1.4) and 5 (9/12, severity 1.1) and basal cell hyperplasia was observed at nasal levels 4 (10/12, severity 1.8) and 5 (11/12, severity 1.3). At 80 ppm, olfactory neuron loss was observed at levels 3 (8/8, severity 2.4), 4 (12/12, severity 2.4), 5 (11/12, severity 1.5), and 6 (5/12, severity 1.2; incidence not statistically significant) and basal cell hyperplasia was observed at nasal levels 4 (12/12, severity 1.2), 5 (11/12, severity 1.3), and 6 (6/12, severity 1.0).

Dose and end point used for MRL derivation:

☒ NOAEL ☐ LOAEL

The MRL is based on a NOAEL of 10 ppm and a LOAEL of 30 ppm for olfactory neuron loss and basal cell hyperplasia in the olfactory epithelium of the nose.

Uncertainty Factors used in MRL derivation:

- ☐ 10 for use of a LOAEL
- ☒ 3 for extrapolation from animals to humans with dosimetric adjustment
- ☒ 10 for human variability

## APPENDIX A

Was a conversion used from ppm in food or water to a mg/body weight dose? None.

If an inhalation study in animals, list the conversion factors used in determining human equivalent dose:

$$\text{NOAEL}_{\text{ADJ}} = 10 \text{ ppm} \times 6 \text{ hour}/24 \text{ hour} \times 7 \text{ days}/7 \text{ days} = 2.5 \text{ ppm}$$

The human equivalent concentration (HEC) was calculated using the following equation (EPA 1994b):

$$\text{NOAEL}_{\text{HEC}} = \text{NOAEL}_{\text{ADJ}} \times \text{RGDR}_{\text{ET}}$$

The regional gas dose ratio for the extrathoracic region ( $\text{RGDR}_{\text{ET}}$ ) of 0.184 was calculated using the following equation:

$$\text{RGDR}_{\text{ET}} = \frac{\left( \frac{V_E}{SA_{\text{ET}}} \right)_{\text{rat}}}{\left( \frac{V_E}{SA_{\text{ET}}} \right)_{\text{human}}}$$

Where:

$V_e$  is the minute volume and  $SA_{\text{ET}}$  is the surface area of the extrathoracic (ET) region of the respiratory tract.

Minute volume ( $V_e$ )

Human: 13.8 L/minute (EPA 1994b)

Rat: 0.190 L/minute; calculated using the following EPA equation:

$$\ln(V_e) = b_0 + b_1 \ln(\text{BW})$$

For rats,  $b_0$  equals -0.578 and  $b_1$  equals 0.821

Because a limited amount of body weight data were reported in the study, a reference body weight of 0.267 kg (EPA 1988) was used.

EPA (1994b) rat and human respiratory surface area reference values:

Extrathoracic	15.0 cm <sup>2</sup> (rat)	200 cm <sup>2</sup> (human)
---------------	----------------------------	-----------------------------

$$\text{NOAEL}_{[\text{HEC}]} = \text{NOAEL (ADJ)} \times \text{RGDR} = 2.5 \text{ ppm} \times 0.184 = 0.46 \text{ ppm}$$

Other additional studies or pertinent information which lend support to this MRL: There are limited data on the toxicity of hydrogen sulfide in humans following intermediate-duration exposure. Acute- and chronic-duration studies suggest that the respiratory tract, cardiovascular system, and nervous system are sensitive targets of hydrogen sulfide.

Intermediate-duration animal studies support the identification of the respiratory tract and nervous system as sensitive targets; cardiovascular effects have not been reported in intermediate-duration animal studies. Exposure of rats and mice to low hydrogen sulfide concentrations have resulted in histological damage to

## APPENDIX A

the upper respiratory tract. Brenneman et al. (2000) reported significant concentration-related increases in the incidence and severity of lesions to the nasal olfactory epithelium in rats exposed to hydrogen sulfide for 10 weeks. The effects consisted of olfactory neuron loss and basal cell hyperplasia in rats exposed to 30 ppm and higher, 6 hours/day, 7 days/week for 10 weeks; no adverse effects were observed at 10 ppm. An earlier studies conducted by CIIT (1983b, 1983c) did not find significant alterations in the nasal turbinates of Sprague-Dawley or F-344 rats exposed to  $\leq 80$  ppm hydrogen sulfide 6 hours/day, 5 days/week for 13 weeks. Inflammation of the squamous portion of the nasal mucosa was observed in mice exposed to 80 ppm hydrogen sulfide 6 hours/day, 5 days/week for 13 weeks (CIIT 1983a); the NOAEL for this effect is 30 ppm. However, a re-examination of the histological specimens from this study (Dorman et al. 2004) revealed significant increases in the incidence of olfactory neuron loss in male and female Sprague-Dawley rats, F-344 rats, and B6C3F<sub>1</sub> mice exposed to 30 or 80 ppm; the NOAEL was 10 ppm. Additionally, significant increases in the incidence of bronchiolar epithelial hypertrophy and hyperplasia were observed in female Sprague-Dawley rats exposed to 30 or 80 ppm and male Sprague-Dawley rats and male F-344 rats exposed to 80 ppm. The sensitivity of the olfactory epithelium has been confirmed by acute-duration studies. Degeneration of the olfactory epithelium was observed in rats exposed to 400 ppm hydrogen sulfide for 4 hours (Lopez et al. 1988b), rats exposed to 200 ppm for 3 hours (Brenneman et al. 2002), and rats exposed to 80 ppm 3 hours/day for 5 days (Brenneman et al. 2002). Data collected using a computational fluid dynamics model of the rat nasal epithelium (Moulin et al. 2002) suggest that the olfactory epithelium is more sensitive than the nasal respiratory epithelium despite the higher hydrogen sulfide flux (a surrogate for dose) to the regions lined with respiratory epithelium compared to regions lined with olfactory epithelium. Within the areas of the nose lined with olfactory epithelium, a high correlation between predicted hydrogen sulfide flux and the incidence of olfactory lesion was found.

The neurotoxicity of hydrogen sulfide following intermediate-duration exposure has not been adequately tested in mature animals; the data are limited to studies assessing brain weight, neurological function (posture, gait, tone of facial muscles, and pupillary reflexes), and histopathology. A 5% decrease in absolute brain weight was observed in Sprague-Dawley rats exposed to 80 ppm hydrogen sulfide 6 hours/day, 5 days/week for 13 weeks; no alterations were observed at 30 ppm (CIIT 1983c). No alterations in histopathology or neurological function were observed in Sprague-Dawley rats (CIIT 1983c), F-344 rats (CIIT 1983b), or B6C3F<sub>1</sub> mice (CIIT 1983a) exposed to concentrations up to 80 ppm 6 hours/day, 5 days/week for 13 weeks. Neurodevelopmental toxicity studies have found some alterations that are suggestive of neurotoxicity. The suggestive findings in the offspring of rats exposed to 20 ppm 7 hours/day on gestational day 5 through postnatal day 21 include alterations in the architecture and growth characteristics of Purkinje cell dendritic fields (Hannah and Roth 1991), decreases in norepinephrine and increases in serotonin in the frontal cortex (Skrajny et al. 1992), and decreases in brain amino acid levels were observed at 75 ppm (Hannah et al. 1989, 1990). However, no alterations in neurobehavioral performance (assessed via motor activity, passive avoidance, acoustic startle, functional observation battery) were observed in the offspring of rats exposed for 2 weeks prior to mating, during mating, on gestational days 5–19, and on postnatal days 5–18 (Dorman et al. 2000). These data suggest that exposures of 20–80 ppm may result in subclinical alterations in neurochemistry.

Agency Contact (Chemical Manager): Selene Chou





## APPENDIX B. USER'S GUIDE

### Chapter 1

#### Public Health Statement

This chapter of the profile is a health effects summary written in non-technical language. Its intended audience is the general public, especially people living in the vicinity of a hazardous waste site or chemical release. If the Public Health Statement were removed from the rest of the document, it would still communicate to the lay public essential information about the chemical.

The major headings in the Public Health Statement are useful to find specific topics of concern. The topics are written in a question and answer format. The answer to each question includes a sentence that will direct the reader to chapters in the profile that will provide more information on the given topic.

### Chapter 2

#### Relevance to Public Health

This chapter provides a health effects summary based on evaluations of existing toxicologic, epidemiologic, and toxicokinetic information. This summary is designed to present interpretive, weight-of-evidence discussions for human health end points by addressing the following questions:

1. What effects are known to occur in humans?
2. What effects observed in animals are likely to be of concern to humans?
3. What exposure conditions are likely to be of concern to humans, especially around hazardous waste sites?

The chapter covers end points in the same order that they appear within the Discussion of Health Effects by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect. Human data are presented first, then animal data. Both are organized by duration (acute, intermediate, chronic). *In vitro* data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also considered in this chapter.

The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using existing toxicokinetic, genotoxic, and carcinogenic data. ATSDR does not currently assess cancer potency or perform cancer risk assessments. Minimal Risk Levels (MRLs) for noncancer end points (if derived) and the end points from which they were derived are indicated and discussed.

Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public health are identified in the Chapter 3 Data Needs section.

#### Interpretation of Minimal Risk Levels

Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral routes of entry at each duration of exposure (acute, intermediate, and chronic). These MRLs are not

## APPENDIX B.

meant to support regulatory action, but to acquaint health professionals with exposure levels at which adverse health effects are not expected to occur in humans.

MRLs should help physicians and public health officials determine the safety of a community living near a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water. MRLs are based largely on toxicological studies in animals and on reports of human occupational exposure.

MRL users should be familiar with the toxicologic information on which the number is based. Chapter 2, "Relevance to Public Health," contains basic information known about the substance. Other sections such as Chapter 3 Section 3.9, "Interactions with Other Substances," and Section 3.10, "Populations that are Unusually Susceptible" provide important supplemental information.

MRL users should also understand the MRL derivation methodology. MRLs are derived using a modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.

To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, represents the most sensitive human health effect for a given exposure route and duration. ATSDR cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available for all potential systemic, neurological, and developmental effects. If this information and reliable quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive species (when information from multiple species is available) with the highest no-observed-adverse-effect level (NOAEL) that does not exceed any adverse effect levels. When a NOAEL is not available, a lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor (UF) of 10 must be employed. Additional uncertainty factors of 10 must be used both for human variability to protect sensitive subpopulations (people who are most susceptible to the health effects caused by the substance) and for interspecies variability (extrapolation from animals to humans). In deriving an MRL, these individual uncertainty factors are multiplied together. The product is then divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used in developing a substance-specific MRL are provided in the footnotes of the levels of significant exposure (LSE) tables.

## **Chapter 3**

### **Health Effects**

#### **Tables and Figures for Levels of Significant Exposure (LSE)**

Tables and figures are used to summarize health effects and illustrate graphically levels of exposure associated with those effects. These levels cover health effects observed at increasing dose concentrations and durations, differences in response by species, MRLs to humans for noncancer end points, and EPA's estimated range associated with an upper-bound individual lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of the health effects and to locate data for a specific exposure scenario. The LSE tables and figures should always be used in conjunction with the text. All entries in these tables and figures represent studies that provide reliable, quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).

The legends presented below demonstrate the application of these tables and figures. Representative examples of LSE Table 3-1 and Figure 3-1 are shown. The numbers in the left column of the legends correspond to the numbers in the example table and figure.

## APPENDIX B.

**LEGEND****See Sample LSE Table 3-1 (page B-6)**

- (1) Route of Exposure. One of the first considerations when reviewing the toxicity of a substance using these tables and figures should be the relevant and appropriate route of exposure. Typically when sufficient data exist, three LSE tables and two LSE figures are presented in the document. The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively). LSE figures are limited to the inhalation (LSE Figure 3-1) and oral (LSE Figure 3-2) routes. Not all substances will have data on each route of exposure and will not, therefore, have all five of the tables and figures.
- (2) Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15–364 days), and chronic (365 days or more)—are presented within each relevant route of exposure. In this example, an inhalation study of intermediate exposure duration is reported. For quick reference to health effects occurring from a known length of exposure, locate the applicable exposure period within the LSE table and figure.
- (3) Health Effect. The major categories of health effects included in LSE tables and figures are death, systemic, immunological, neurological, developmental, reproductive, and cancer. NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer. Systemic effects are further defined in the "System" column of the LSE table (see key number 18).
- (4) Key to Figure. Each key number in the LSE table links study information to one or more data points using the same key number in the corresponding LSE figure. In this example, the study represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL (also see the two "18r" data points in sample Figure 3-1).
- (5) Species. The test species, whether animal or human, are identified in this column. Chapter 2, "Relevance to Public Health," covers the relevance of animal data to human toxicity and Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics. Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent human doses to derive an MRL.
- (6) Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure regimens are provided in this column. This permits comparison of NOAELs and LOAELs from different studies. In this case (key number 18), rats were exposed to "Chemical x" via inhalation for 6 hours/day, 5 days/week, for 13 weeks. For a more complete review of the dosing regimen, refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 1981).
- (7) System. This column further defines the systemic effects. These systems include respiratory, cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered in these systems. In the example of key number 18, one systemic effect (respiratory) was investigated.
- (8) NOAEL. A NOAEL is the highest exposure level at which no harmful effects were seen in the organ system studied. Key number 18 reports a NOAEL of 3 ppm for the respiratory system,

## APPENDIX B.

which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see footnote "b").

- (9) LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect. LOAELs have been classified into "Less Serious" and "Serious" effects. These distinctions help readers identify the levels of exposure at which adverse health effects first appear and the gradation of effects with increasing dose. A brief description of the specific end point used to quantify the adverse effect accompanies the LOAEL. The respiratory effect reported in key number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm. MRLs are not derived from Serious LOAELs.
- (10) Reference. The complete reference citation is given in Chapter 9 of the profile.
- (11) CEL. A CEL is the lowest exposure level associated with the onset of carcinogenesis in experimental or epidemiologic studies. CELs are always considered serious effects. The LSE tables and figures do not contain NOAELs for cancer, but the text may report doses not causing measurable cancer increases.
- (12) Footnotes. Explanations of abbreviations or reference notes for data in the LSE tables are found in the footnotes. Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to derive an MRL of 0.005 ppm.

**LEGEND**

**See Sample Figure 3-1 (page B-7)**

LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the reader quickly compare health effects according to exposure concentrations for particular exposure periods.

- (13) Exposure Period. The same exposure periods appear as in the LSE table. In this example, health effects observed within the acute and intermediate exposure periods are illustrated.
- (14) Health Effect. These are the categories of health effects for which reliable quantitative data exists. The same health effects appear in the LSE table.
- (15) Levels of Exposure. Concentrations or doses for each health effect in the LSE tables are graphically displayed in the LSE figures. Exposure concentration or dose is measured on the log scale "y" axis. Inhalation exposure is reported in mg/m<sup>3</sup> or ppm and oral exposure is reported in mg/kg/day.
- (16) NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in the rat upon which an intermediate inhalation exposure MRL is based. The key number 18 corresponds to the entry in the LSE table. The dashed descending arrow indicates the extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of 0.005 ppm (see footnote "b" in the LSE table).
- (17) CEL. Key number 38m is one of three studies for which CELs were derived. The diamond symbol refers to a CEL for the test species-mouse. The number 38 corresponds to the entry in the LSE table.

## APPENDIX B.

- (18) Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. These risk levels are derived from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the cancer dose response curve at low dose levels ( $q_1^*$ ).
- (19) Key to LSE Figure. The Key explains the abbreviations and symbols used in the figure.

## SAMPLE

1 →

Table 3-1. Levels of Significant Exposure to [Chemical x] – Inhalation


	Key to figure <sup>a</sup>	Species	Exposure frequency/ duration	System	NOAEL (ppm)	LOAEL (effect)		Reference
						Less serious (ppm)	Serious (ppm)	
2	→	INTERMEDIATE EXPOSURE						
		5	6	7	8	9		10
3	→	Systemic	↓	↓	↓	↓		↓
4	→	18	Rat	13 wk 5 d/wk 6 hr/d	Resp	3 <sup>b</sup>	10 (hyperplasia)	Nitschke et al. 1981
		CHRONIC EXPOSURE						
		Cancer					11	
						↓		
		38	Rat	18 mo 5 d/wk 7 hr/d		20	(CEL, multiple organs)	Wong et al. 1982
		39	Rat	89–104 wk 5 d/wk 6 hr/d		10	(CEL, lung tumors, nasal tumors)	NTP 1982
		40	Mouse	79–103 wk 5 d/wk 6 hr/d		10	(CEL, lung tumors, hemangiosarcomas)	NTP 1982

12 →

<sup>a</sup> The number corresponds to entries in Figure 3-1.<sup>b</sup> Used to derive an intermediate inhalation Minimal Risk Level (MRL) of  $5 \times 10^{-3}$  ppm; dose adjusted for intermittent exposure and divided by an uncertainty factor of 100 (10 for extrapolation from animal to humans, 10 for human variability).

# SAMPLE

**Figure 3-1. Levels of Significant Exposure to [Chemical X] - Inhalation**







## APPENDIX C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS

ACGIH	American Conference of Governmental Industrial Hygienists
ACOEM	American College of Occupational and Environmental Medicine
ADI	acceptable daily intake
ADME	absorption, distribution, metabolism, and excretion
AED	atomic emission detection
AFID	alkali flame ionization detector
AFOSH	Air Force Office of Safety and Health
ALT	alanine aminotransferase
AML	acute myeloid leukemia
AOAC	Association of Official Analytical Chemists
AOEC	Association of Occupational and Environmental Clinics
AP	alkaline phosphatase
APHA	American Public Health Association
AST	aspartate aminotransferase
atm	atmosphere
ATSDR	Agency for Toxic Substances and Disease Registry
AWQC	Ambient Water Quality Criteria
BAT	best available technology
BCF	bioconcentration factor
BEI	Biological Exposure Index
BMD	benchmark dose
BMR	benchmark response
BSC	Board of Scientific Counselors
C	centigrade
CAA	Clean Air Act
CAG	Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS	Chemical Abstract Services
CDC	Centers for Disease Control and Prevention
CEL	cancer effect level
CELDS	Computer-Environmental Legislative Data System
CERCLA	Comprehensive Environmental Response, Compensation, and Liability Act
CFR	Code of Federal Regulations
Ci	curie
CI	confidence interval
CL	ceiling limit value
CLP	Contract Laboratory Program
cm	centimeter
CML	chronic myeloid leukemia
CPSC	Consumer Products Safety Commission
CWA	Clean Water Act
DHEW	Department of Health, Education, and Welfare
DHHS	Department of Health and Human Services
DNA	deoxyribonucleic acid
DOD	Department of Defense
DOE	Department of Energy
DOL	Department of Labor
DOT	Department of Transportation

## APPENDIX C

DOT/UN/	Department of Transportation/United Nations/
NA/IMCO	North America/International Maritime Dangerous Goods Code
DWEL	drinking water exposure level
ECD	electron capture detection
ECG/EKG	electrocardiogram
EEG	electroencephalogram
EEGL	Emergency Exposure Guidance Level
EPA	Environmental Protection Agency
F	Fahrenheit
F <sub>1</sub>	first-filial generation
FAO	Food and Agricultural Organization of the United Nations
FDA	Food and Drug Administration
FEMA	Federal Emergency Management Agency
FEV <sub>1</sub>	forced expiratory volume in 1 second
FIFRA	Federal Insecticide, Fungicide, and Rodenticide Act
FVC	forced vital capacity
FPD	flame photometric detection
fpm	feet per minute
FR	Federal Register
FSH	follicle stimulating hormone
g	gram
GC	gas chromatography
gd	gestational day
GLC	gas liquid chromatography
GPC	gel permeation chromatography
HPLC	high-performance liquid chromatography
HRGC	high resolution gas chromatography
HSDB	Hazardous Substance Data Bank
IARC	International Agency for Research on Cancer
IDLH	immediately dangerous to life and health
ILO	International Labor Organization
IRIS	Integrated Risk Information System
K <sub>d</sub>	adsorption ratio
kg	kilogram
kgg	metric ton
K <sub>oc</sub>	organic carbon partition coefficient
K <sub>ow</sub>	octanol-water partition coefficient
L	liter
LC	liquid chromatography
LC <sub>50</sub>	lethal concentration, 50% kill
LC <sub>Lo</sub>	lethal concentration, low
LD <sub>50</sub>	lethal dose, 50% kill
LD <sub>Lo</sub>	lethal dose, low
LDH	lactic dehydrogenase
LH	luteinizing hormone
LOAEL	lowest-observed-adverse-effect level
LSE	Levels of Significant Exposure
LT <sub>50</sub>	lethal time, 50% kill
m	meter
MA	<i>trans,trans</i> -muconic acid
MAL	maximum allowable level

## APPENDIX C

mCi	millicurie
MCL	maximum contaminant level
MCLG	maximum contaminant level goal
MF	modifying factor
MFO	mixed function oxidase
mg	milligram
mL	milliliter
mm	millimeter
mmHg	millimeters of mercury
mmol	millimole
mppcf	millions of particles per cubic foot
MRL	Minimal Risk Level
MS	mass spectrometry
NAAQS	National Ambient Air Quality Standard
NAS	National Academy of Science
NATICH	National Air Toxics Information Clearinghouse
NATO	North Atlantic Treaty Organization
NCE	normochromatic erythrocytes
NCEH	National Center for Environmental Health
NCI	National Cancer Institute
ND	not detected
NFPA	National Fire Protection Association
ng	nanogram
NHANES	National Health and Nutrition Examination Survey
NIEHS	National Institute of Environmental Health Sciences
NIOSH	National Institute for Occupational Safety and Health
NIOSHTIC	NIOSH's Computerized Information Retrieval System
NLM	National Library of Medicine
nm	nanometer
nmol	nanomole
NOAEL	no-observed-adverse-effect level
NOES	National Occupational Exposure Survey
NOHS	National Occupational Hazard Survey
NPD	nitrogen phosphorus detection
NPDES	National Pollutant Discharge Elimination System
NPL	National Priorities List
NR	not reported
NRC	National Research Council
NS	not specified
NSPS	New Source Performance Standards
NTIS	National Technical Information Service
NTP	National Toxicology Program
ODW	Office of Drinking Water, EPA
OERR	Office of Emergency and Remedial Response, EPA
OHM/TADS	Oil and Hazardous Materials/Technical Assistance Data System
OPP	Office of Pesticide Programs, EPA
OPPT	Office of Pollution Prevention and Toxics, EPA
OPPTS	Office of Prevention, Pesticides and Toxic Substances, EPA
OR	odds ratio
OSHA	Occupational Safety and Health Administration
OSW	Office of Solid Waste, EPA

## APPENDIX C

OTS	Office of Toxic Substances
OW	Office of Water
OWRS	Office of Water Regulations and Standards, EPA
PAH	polycyclic aromatic hydrocarbon
PBPD	physiologically based pharmacodynamic
PBPK	physiologically based pharmacokinetic
PCE	polychromatic erythrocytes
PEL	permissible exposure limit
pg	picogram
PHS	Public Health Service
PID	photo ionization detector
pmol	picomole
PMR	proportionate mortality ratio
ppb	parts per billion
ppm	parts per million
ppt	parts per trillion
PSNS	pretreatment standards for new sources
RBC	red blood cell
REL	recommended exposure level/limit
RfC	reference concentration
RfD	reference dose
RNA	ribonucleic acid
RQ	reportable quantity
RTECS	Registry of Toxic Effects of Chemical Substances
SARA	Superfund Amendments and Reauthorization Act
SCE	sister chromatid exchange
SGOT	serum glutamic oxaloacetic transaminase
SGPT	serum glutamic pyruvic transaminase
SIC	standard industrial classification
SIM	selected ion monitoring
SIR	standardized incidence ratio
SMCL	secondary maximum contaminant level
SMR	standardized mortality ratio
SNARL	suggested no adverse response level
SPEGL	Short-Term Public Emergency Guidance Level
STEL	short term exposure limit
STORET	Storage and Retrieval
TD <sub>50</sub>	toxic dose, 50% specific toxic effect
TLV	threshold limit value
TOC	total organic carbon
TPQ	threshold planning quantity
TRI	Toxics Release Inventory
TRS	total reduced sulfur
TSCA	Toxic Substances Control Act
TWA	time-weighted average
UF	uncertainty factor
U.S.	United States
USDA	United States Department of Agriculture
USGS	United States Geological Survey
VOC	volatile organic compound
VO <sub>2</sub>	oxygen uptake

## APPENDIX C

VCO <sub>2</sub>	carbon dioxide uptake
WBC	white blood cell
WHO	World Health Organization

>	greater than
≥	greater than or equal to
=	equal to
<	less than
≤	less than or equal to
%	percent
α	alpha
β	beta
γ	gamma
δ	delta
μm	micrometer
μg	microgram
q <sub>1</sub> <sup>*</sup>	cancer slope factor
–	negative
+	positive
(+)	weakly positive result
(–)	weakly negative result



## APPENDIX D. INDEX

absorbed dose .....	93
adsorption .....	137
aerobic .....	58, 61, 98
ambient air .....	119, 125, 127, 130, 134
anaerobic .....	14, 87, 121, 129
anemia .....	57, 103
AST .....	58
biomarker .....	92, 93, 106
biomarkers .....	92, 93, 94, 106, 137
body weight effects .....	61, 73, 74
breast milk .....	129, 131, 132
cancer .....	4, 5, 11, 72, 73, 91, 103
carcinogen .....	103
carcinogenic .....	19, 20, 103
carcinogenicity .....	12, 103
cardiac arrhythmia .....	10, 55, 56
cardiovascular .....	23, 55, 56, 73, 74, 101
cardiovascular effects .....	54, 55, 101
cognitive function .....	64, 98
cytochrome oxidase .....	12, 14, 53, 62, 67, 82, 87, 97, 98, 107
death .....	19, 21, 24, 73, 74, 77, 78, 87, 91, 101, 105, 129
dermal effects .....	59
DNA .....	92
endocrine .....	59, 73, 74, 89
endocrine effects .....	59
erythema .....	59
fetus .....	90, 132
gastrointestinal effects .....	56, 57, 73
general population .....	3, 6, 10, 92, 96, 119, 130
genotoxic .....	19
genotoxicity .....	75, 103
groundwater .....	120, 121, 122, 134
half-life .....	92
hematological effects .....	57
hepatic effects .....	58
hydroxyl radical .....	119, 123
immunological .....	19, 62, 75, 101
immunological effects .....	62
knockdown .....	10, 47, 63
$K_{ow}$ .....	111
lymphoreticular .....	62, 75, 101
metabolic effects .....	14, 61, 73
milk .....	97, 129, 132
musculoskeletal effects .....	58
neurobehavioral .....	11, 13, 16, 62, 66, 71, 89, 104
neurodevelopmental .....	17
norepinephrine .....	16, 72
nuclear .....	115
ocular effects .....	11, 60, 101
odds ratio .....	47, 48, 49
pharmacodynamic .....	84
pharmacokinetic .....	77, 84, 85, 86, 90, 101, 102, 103

## APPENDIX D

rate constant.....	119, 123
renal effects .....	58, 59
retention.....	63, 94
SGOT.....	58, 70
solubility .....	76, 103, 122, 128, 134
thiosulfate .....	6, 76, 79, 80, 83, 88, 93, 97, 106, 107, 138, 139, 140, 144, 145, 148, 150
thyroid .....	59
toxicokinetic .....	19, 88, 107
tremors.....	17, 62, 63, 105
vapor phase.....	129
volatility.....	137